List of Pomalyst drug patents

Pomalyst is owned by Celgene.

Pomalyst contains Pomalidomide.

Pomalyst has a total of 12 drug patents out of which 0 drug patents have expired.

Pomalyst was authorised for market use on 08 February, 2013.

Pomalyst is available in capsule;oral dosage forms.

Pomalyst can be used as use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma, use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy.

The generics of Pomalyst are possible to be released after 21 December, 2031.

POMALYST's oppositions filed in EPO
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8828427 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673939 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(a month from now)

US8735428 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(a month from now)

US8735428

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(7 months from now)

US8673939

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(7 months from now)

US8198262 CELGENE Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Jun, 2025

(2 years from now)

US8198262

(Pediatric)

CELGENE Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Dec, 2025

(2 years from now)

US9993467 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(7 years from now)

US10555939 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(7 years from now)

US9993467

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(7 years from now)

US10555939

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(7 years from now)

US8828427

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Dec, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
M (M) Nov 20, 2023
Orphan Drug Exclusivity (ODE) May 14, 2027
Pediatric Exclusivity (PED) May 20, 2024

Drugs and Companies using POMALIDOMIDE ingredient

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy

Dosage: CAPSULE;ORAL

How can I launch a generic of POMALYST before it's patent expiration?
More Information on Dosage

POMALYST family patents

97

United States

29

China

28

Canada

27

European Union

24

Japan

14

New Zealand

14

Korea, Republic of

14

Australia

13

Mexico

10

Israel

9

Portugal

9

Spain

9

Hong Kong

9

Denmark

8

South Africa

7

Poland

6

Brazil

6

Norway

6

Taiwan, Province of China

6

Slovenia

5

Costa Rica

5

Cyprus

5

Hungary

4

Russia

4

Ukraine

3

Croatia

3

Argentina

3

Peru

3

ME

3

Ecuador

2

Austria

2

Lithuania

2

Iceland

2

RS

1

Turkey

1

Germany

1

Singapore

1

San Marino

1

Colombia

1

AP

1

Philippines

1

Morocco

1

EA

1

Nicaragua

1

Luxembourg

1

Yugoslavia

1

OA

1

Georgia

1

Chile

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic